Keribin Pierre, Guerrot Dominique, Jardin Fabrice, Moizan Hervé
Resident, Department of Oral Surgery and Odontology, Rouen University Hospital, Rouen, France.
Professor and Head of Department, Normandie University, UNIROUEN, Inserm U1096, and Department of Nephrology, Rouen University Hospital, Rouen, France.
J Oral Maxillofac Surg. 2017 Dec;75(12):2599-2605. doi: 10.1016/j.joms.2017.05.016. Epub 2017 May 24.
Osteonecrosis of the jaw (ONJ) is a rare but potentially severe condition that can be induced by specific treatments. We report the case of a 69-year-old male kidney transplant recipient who presented with ONJ 5 years after transplantation. The patient presented with ulcerations of the oral mucosa related to post-transplantation lymphoproliferative disorder, which was treated with rituximab. Subsequently, ONJ developed. Although rituximab treatment cannot be firmly established as the cause of this condition, similar cases of ONJ have been reported after treatment with this monoclonal antibody. This case raises a potential link between rituximab treatment and ONJ and prompts further studies to investigate the potential impact of rituximab on bone angiogenesis.
颌骨骨坏死（ONJ）是一种罕见但可能严重的病症，可由特定治疗引发。我们报告一例69岁男性肾移植受者的病例，该患者在移植后5年出现ONJ。患者出现与移植后淋巴细胞增生性疾病相关的口腔黏膜溃疡，接受了利妥昔单抗治疗。随后，发生了ONJ。虽然不能确凿地认定利妥昔单抗治疗是导致这种病症的原因，但使用这种单克隆抗体治疗后已有类似ONJ病例的报告。该病例提出了利妥昔单抗治疗与ONJ之间的潜在联系，并促使进一步研究以调查利妥昔单抗对骨血管生成的潜在影响。
